Affordable Access

Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. A randomized, double-masked, long-term clinical trial (1).

Authors
  • Kass, M A
  • Gordon, M O
  • Hoff, M R
  • Parkinson, J M
  • Kolker, A E
  • Hart, W M Jr
  • Becker, B
Type
Published Article
Journal
Journal of glaucoma
Publication Date
Jan 01, 1993
Volume
2 Suppl A
Pages
1–2
Identifiers
PMID: 19920456
Source
Medline
License
Unknown

Abstract

One eye was chosen randomly to receive timolol therapy twice daily; the fellow eye received placebo (timolol vehicle). The primary end point of the study was reproducible visual field loss detected on three consecutive tests. Automated static threshold visual fields were added to the protocol as the study proceeded, and criteria for reproducible defects for the automated fields were developed. The secondary end point was progressive optic disc cupping confirmed by examination of stereoscopic disc photographs. Intraocular pressure was not used as an end point (i.e., eyes were not withdrawn from the study because they reached a predetermined level of intraocular pressure).

Report this publication

Statistics

Seen <100 times